[Radioimmunologic determination of the progestagen dienogest in plasma and saliva]

Die Pharmazie · 1986 · vol. 41(11) , pp. 772–4 · PMID:3484359 · W2474895049
Other OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

A radioimmunoassay was used to measure dienogest in plasma and saliva, finding high correlation between the two and a similar elimination half-life, suggesting a high unbound fraction and no accumulation after repeated dosing.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Following oral administration of 2 mg of dienogest (17 alpha-cyanomethyl-17 beta-hydroxy-4,9-estradien-3-one) to female volunteers, the dienogest concentration courses in plasma and saliva were determined by means of a specific radioimmunoassay (RIA). Three different procedures of the plasma sample preparation prior to the RIA were compared. The dienogest RIA was directly applied to saliva. There is a high correlation between the dienogest concentrations in plasma and saliva. The dienogest plasma elimination half life of about 9 hrs is not significantly different from that derived from saliva. The salivary dienogest concentrations indicate a relatively high non-protein bound portion of this steroid drug in plasma. Following repeated oral administration of dienogest (tau = 24 hrs), there is no significant cumulation of plasma dienogest.

My notes (saved in your browser only)

MeSH descriptors

Nandrolone Progesterone Congeners Saliva Administration, Oral Humans Kinetics Nandrolone Nandrolone Nandrolone Progesterone Congeners Progesterone Congeners Radioimmunoassay Saliva

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T11:27:52.549276+00:00
pubmed
last seen: 2026-10-08T21:33:14.624860+00:00
License: CC0 · commercial use OK